文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

跨性别成年人的激素治疗。

Hormone Therapy for Transgender Adults.

机构信息

Callen-Lorde Community Health Center, 356 West 18th Street, New York, NY 10011, USA; Department of Medicine, NYU School of Medicine, New York, NY, USA.

出版信息

Urol Clin North Am. 2019 Nov;46(4):467-473. doi: 10.1016/j.ucl.2019.07.001. Epub 2019 Aug 19.


DOI:10.1016/j.ucl.2019.07.001
PMID:31582021
Abstract

Transgender people have a gender identity that differs from their sex assigned at birth. For many transgender individuals accessing gender affirming hormone therapy (GAHT) is an important and medically necessary step in their gender transition. Both feminizing and masculinizing regimens are safe when used within established hormone protocols and are associated with significant improvements in mental health outcomes, including reduction in depression, anxiety and gender dysphoria. Clinicians should be aware of the current best practice guidelines for initiating and maintaining patients on GAHT.

摘要

跨性别者的性别认同与其出生时被分配的性别不同。对于许多跨性别者来说,获得性别肯定激素治疗(GAHT)是他们性别过渡中的一个重要且医学上必需的步骤。在既定的激素方案内使用女性化和男性化方案都是安全的,并且与心理健康结果的显著改善相关,包括减少抑郁、焦虑和性别焦虑。临床医生应该了解目前关于启动和维持 GAHT 患者的最佳实践指南。

相似文献

[1]
Hormone Therapy for Transgender Adults.

Urol Clin North Am. 2019-8-19

[2]
MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.

Eur J Endocrinol. 2021-6-28

[3]
Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.

Front Endocrinol (Lausanne). 2024

[4]
Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition.

Curr Psychiatry Rep. 2018-10-11

[5]
Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: a quantitative systematic review.

JBI Database System Rev Implement Rep. 2019-9

[6]
Cardiovascular implications of gender-affirming hormone treatment in the transgender population.

Maturitas. 2019-8-20

[7]
Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people.

J Endocrinol Invest. 2024-5

[8]
Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.

Endocrine. 2024-7

[9]
Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.

Pharmacotherapy. 2014-12

[10]
Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study.

Andrology. 2021-11

引用本文的文献

[1]
New challenges in the management of inflammatory bowel disease: a case study.

Prz Gastroenterol. 2025

[2]
Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.

Front Endocrinol (Lausanne). 2024

[3]
Exposomics as a tool to investigate differences in health and disease by sex and gender.

Exposome. 2023-3-21

[4]
Transgender and Alagille Syndrome: A Rare Case of a Trans Woman with Alagille Syndrome.

Transgend Health. 2023-2-8

[5]
Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.

Cancers (Basel). 2022-12-30

[6]
Epilepsy Care in Transgender Patients.

Curr Neurol Neurosci Rep. 2022-8

[7]
Current use of testosterone therapy in LGBTQ populations.

Int J Impot Res. 2022-11

[8]
Macular Abnormalities Associated With 5α-Reductase Inhibitor.

JAMA Ophthalmol. 2020-7-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索